| Literature DB >> 28747217 |
Atqah AbdulWahab1,2, Husam Salah3,4, Prem Chandra5, Saad J Taj-Aldeen6,3.
Abstract
OBJECTIVES: Candida dubliniensis is an emerging yeast and demonstrated a high adherence property to cystic fibrosis respiratory tract. Therefore, it is important to determine the persistence of C. dubliniensis and to assess the possible relationship to the body mass index (BMI) and forced expiratory volume in 1st second (FEV1).Entities:
Keywords: BMI; Candida dubliniensis; Cystic fibrosis; FEV1%; Lung function
Mesh:
Year: 2017 PMID: 28747217 PMCID: PMC5530559 DOI: 10.1186/s13104-017-2656-z
Source DB: PubMed Journal: BMC Res Notes ISSN: 1756-0500
Summary of clinical characteristics between two CF groups ≤18 years and >18 years
| Parameters | ≤18 years (N = 38) | >18 years (N = 14) | P |
|---|---|---|---|
| N(%) | N(%) | ||
| Sex/male | 21 (55.3) | 9 (64.3) | 0.559 |
| No. of CF patients with CFTR 1234 V mutation | 30 (78.9) | 14 (100%) | 0.062 |
| No. of CF patients with other CFTR mutation | 8 (21.1) | 0 | 0.130 |
| No. of CF patients with pancreatic sufficiency | 30 (78.9) | 12 (85.7) | 0.583 |
| No. of CF patients with CF related diabetes | 1 (2.6) | 4 (28.6) | 0.005 |
| Nebulized tobramycin use | 14 (36.8) | 11 (78.6) | 0.008 |
| Oral zithromax use | 1 (2.6) | 8 (57.1) | <0.001 |
| Nebulized pulmozyme use | 24 (63.2) | 13 (92.9) | 0.036 |
| Nebulized hypertonic saline use | 9 (23.7) | 7 (50) | 0.142 |
Summary of clinical characteristics between 2 CF groups age ≤18 years and >18 years with Candida dubliniensis
| Parameters | ≤18 years (N = 18) | >18 years (N = 11) | P |
|---|---|---|---|
| N(%) | N(%) | ||
| Sex/male | 10 (55.6) | 7 (63.6) | 0.668 |
| No. of CF patients with CFTR 1234 V mutation | 18 (100) | 11 (100) | |
| No. of CF patients with pancreatic sufficiency | 18 (100) | 10 (90.9) | 0.193 |
| No. of CF patients with CF related diabetes | 0 (0) | 4 (36.4) | 0.014 |
| Nebulized Tobramycin use | 7 (38.9) | 8 (72.7) | 0.077 |
| Oral zythromax use | 0 (0) | 6 (54.5) | 0.001 |
| Nebulized pulmozyme use | 12 (66.7) | 10 (90.9) | 0.139 |
| Nebulized hypertonic saline use | 5 (27.8) | 6 (54.5) | 0.149 |
Fig. 1a The mean BMI of CF patients with the persistence and intermittent existence of C. dubliniensis during the study period. b The mean FEV1 of CF patients with the persistence and intermittent existence of C. dubliniensis during the study period